Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lidocaine HydrochlorideThird Party Manufacturing in India

Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lidocaine Hydrochloride works by combining four distinct therapeutic actions to resolve complex mixed infections and associated discomfort. Beclomethasone dipropionate decreases inflammation by inhibiting phospholipase A2, reducing arachidonic acid release. Neomycin sulphate binds to the 30S ribosomal subunit of susceptible bacteria, disrupting protein synthesis. Clotrimazole alters fungal cell membrane permeability by binding to phospholipids and inhibiting ergosterol synthesis. Lidocaine hydrochloride blocks voltage-gated sodium channels along the nerve axon to stop pain signal propagation. Unlike single-agent therapies, it concurrently resolves inflammation, bacterial proliferation, fungal activity, and acute localized pain. It is highly effective and well-tolerated.

Therapeutic Uses

• Mixed Eye and Ear Infections: Indicated for managing complex ocular or otic conditions involving concurrent bacterial and fungal infections accompanied by severe inflammation.
• Post-Surgical Inflammation: Used to prevent secondary microbial contamination while managing localized pain and edema following specialized procedures.

Why Manufacturers Choose Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lidocaine Hydrochloride

This multi-action combination product commands high market demand because it eliminates the need for multiple single-ingredient drops, driving excellent patient compliance. Brands seeking Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lidocaine Hydrochloride third party manufacturing in India benefit from our partner network optimized for specialized sterile solutions. Our partner facilities are WHO-GMP certified, ensuring strict compliance with international manufacturing guidelines, making it a lucrative product for domestic markets and export portfolios.